Pharmacological blockade of PKR or ISR mitigates PVOD phenotypes in both age groups, suggesting that targeting the PKR/ISR axis could be a potential therapeutic strategy for PVOD. The gene discussed is EIF2AK2; the disease is pulmonary venoocclusive disease.